Alkannin protects human renal proximal tubular epithelial cells from LPS-induced inflammatory injury by regulation of microRNA-210.
Lupus nephritis (LN) is a fatal complication induced by systemic lupus erythematosus (SLE). As the current therapeutic approaches for LN are not a permanent cure, we studied the potential therapeutic effects of alkannin (ALK) on LPS-treated human proximal tubular cells (HK-2 cells), aiming to find novel therapeutic drugs for LN treatment. Cell viability, apoptotic cells, expression of p53 and proteins associated with apoptosis, and release of IL-6 and TNF-α in LPS-treated HK-2 cells were measured by using CCK-8 assay, flow cytometry assay, Western blot analysis and RT-qPCR/ELISA, respectively. Effects of ALK on LPS-treated HK-2 cells were evaluated, and miR-210 expression was determined by RT-qPCR. Afterwards, whether ALK affected LPS-treated cells via regulating miR-210 was verified, and the involvements of the NF-κB and p38MAPK pathways were finally studied using Western blot analysis. LPS-induced decrease of cell viability, increase of apoptosis, and release of IL-6 and TNF-α were attenuated by ALK treatment. We found miR-210 level in LPS-treated cells was elevated by ALK, and miR-210 inhibition could effectively reverse the effects of ALK on LPS-treated cells. Moreover, we found the phosphorylation levels of key kinases in the NF-κB and p38MAPK pathways were reduced by ALK via up-regulating miR-210 in LPS-treated cells. ALK attenuated LPS-induced inflammatory injury in HK-2 cells possibly through up-regulating miR-210. The LPS-induced activation of the NF-κB and p38MAPK pathways was attenuated by ALK via regulation of miR-210.